DE4206045A1 - Sulfonylbenzyl substituierte pyridone - Google Patents

Sulfonylbenzyl substituierte pyridone

Info

Publication number
DE4206045A1
DE4206045A1 DE4206045A DE4206045A DE4206045A1 DE 4206045 A1 DE4206045 A1 DE 4206045A1 DE 4206045 A DE4206045 A DE 4206045A DE 4206045 A DE4206045 A DE 4206045A DE 4206045 A1 DE4206045 A1 DE 4206045A1
Authority
DE
Germany
Prior art keywords
carbon atoms
chain
straight
branched alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE4206045A
Other languages
German (de)
English (en)
Inventor
Rudolf Dr Hanko
Walter Dr Huebsch
Juergen Dressel
Peter Dr Fey
Thomas Dr Kraemer
Ulrich Dr Mueller
Matthias Dr Mueller-Gliemann
Martin Dr Beuck
Stanislav Prof Dr Kazda
Claudia Dr Hirth-Dietrich
Andreas Dr Knorr
Johannes-Peter Dr Stasch
Stefan Dr Wohlfeil
Oezkan Dr Yalkinoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to DE4206045A priority Critical patent/DE4206045A1/de
Priority to TW082100802A priority patent/TW230206B/zh
Priority to CZ93157A priority patent/CZ15793A3/cs
Priority to MX9300766A priority patent/MX9300766A/es
Priority to EP19930102326 priority patent/EP0557843A3/de
Priority to US08/019,000 priority patent/US5254543A/en
Priority to IL104843A priority patent/IL104843A0/xx
Priority to AU33770/93A priority patent/AU653288B2/en
Priority to CA002090267A priority patent/CA2090267A1/en
Priority to NZ245999A priority patent/NZ245999A/en
Priority to JP5061017A priority patent/JPH0641081A/ja
Priority to PL29787093A priority patent/PL297870A1/xx
Priority to HU9300545A priority patent/HUT64057A/hu
Priority to ZA931370A priority patent/ZA931370B/xx
Priority to SK14593A priority patent/SK14593A3/sk
Priority to MYPI93000350A priority patent/MY129973A/en
Priority to KR1019930002728A priority patent/KR930017898A/ko
Priority to CN 93102232 priority patent/CN1078468A/zh
Publication of DE4206045A1 publication Critical patent/DE4206045A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
DE4206045A 1992-02-27 1992-02-27 Sulfonylbenzyl substituierte pyridone Withdrawn DE4206045A1 (de)

Priority Applications (18)

Application Number Priority Date Filing Date Title
DE4206045A DE4206045A1 (de) 1992-02-27 1992-02-27 Sulfonylbenzyl substituierte pyridone
TW082100802A TW230206B (enExample) 1992-02-27 1993-02-06
CZ93157A CZ15793A3 (en) 1992-02-27 1993-02-09 Sulfonylbenzyl-substituted pyridones
MX9300766A MX9300766A (es) 1992-02-27 1993-02-12 Piridonas sustituidas por sulfonilbencilo, procedimiento para su obtencion y medicamentos que las contienen.
EP19930102326 EP0557843A3 (en) 1992-02-27 1993-02-15 Sulfonylbenzyl-substituted pyridones as pharmaceuticals
US08/019,000 US5254543A (en) 1992-02-27 1993-02-18 Sulphonylbenzyl-substituted pyridones which are angiotension II receptor antagonists
IL104843A IL104843A0 (en) 1992-02-27 1993-02-24 Sulphonylbenzyl-substituted pyridones,their preparation and pharmaceutical compositions containing them
AU33770/93A AU653288B2 (en) 1992-02-27 1993-02-24 Sulphonylbenzyl-substituted pyridones
CA002090267A CA2090267A1 (en) 1992-02-27 1993-02-24 Sulphonylbenzyl-substituted pyridones
NZ245999A NZ245999A (en) 1992-02-27 1993-02-25 Pyridone-methyl-phenyl-sulphonyl substituted saturated nitrogen-containing heterocyclic compounds and medicaments
JP5061017A JPH0641081A (ja) 1992-02-27 1993-02-25 スルホニルベンジル−置換されたピリドン類
PL29787093A PL297870A1 (en) 1992-02-27 1993-02-25 Substituted sulfonylbenzylopyridones as well as method of obtaining and drugs containing them
HU9300545A HUT64057A (en) 1992-02-27 1993-02-26 Process for producing sulfonylbenzyl-substituted pyridone derivatives and pahrmaceutical compositions comprising same
ZA931370A ZA931370B (en) 1992-02-27 1993-02-26 Sulfonylbenzyl-substituted pyridones.
SK14593A SK14593A3 (en) 1992-02-27 1993-02-26 Sulfonylbenzyl substituted pyridones
MYPI93000350A MY129973A (en) 1992-02-27 1993-02-26 Sulphonylbenzyl-substituted pyridones.
KR1019930002728A KR930017898A (ko) 1992-02-27 1993-02-26 술포닐벤질 치환 피리돈
CN 93102232 CN1078468A (zh) 1992-02-27 1993-02-27 磺酰苄基取代的吡啶酮

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4206045A DE4206045A1 (de) 1992-02-27 1992-02-27 Sulfonylbenzyl substituierte pyridone

Publications (1)

Publication Number Publication Date
DE4206045A1 true DE4206045A1 (de) 1993-09-02

Family

ID=6452730

Family Applications (1)

Application Number Title Priority Date Filing Date
DE4206045A Withdrawn DE4206045A1 (de) 1992-02-27 1992-02-27 Sulfonylbenzyl substituierte pyridone

Country Status (18)

Country Link
US (1) US5254543A (enExample)
EP (1) EP0557843A3 (enExample)
JP (1) JPH0641081A (enExample)
KR (1) KR930017898A (enExample)
CN (1) CN1078468A (enExample)
AU (1) AU653288B2 (enExample)
CA (1) CA2090267A1 (enExample)
CZ (1) CZ15793A3 (enExample)
DE (1) DE4206045A1 (enExample)
HU (1) HUT64057A (enExample)
IL (1) IL104843A0 (enExample)
MX (1) MX9300766A (enExample)
MY (1) MY129973A (enExample)
NZ (1) NZ245999A (enExample)
PL (1) PL297870A1 (enExample)
SK (1) SK14593A3 (enExample)
TW (1) TW230206B (enExample)
ZA (1) ZA931370B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4215587A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
JPH06306073A (ja) * 1992-12-10 1994-11-01 Japan Tobacco Inc ニコチン誘導体の光学分割法
AU3196100A (en) * 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Lxrのモジュレーター
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
SI1490064T1 (sl) * 2002-02-14 2010-01-29 Pharmacia Corp Substituirani piridinoni kot modulatorji p38 MAP kinaze
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
MX2007011453A (es) 2005-04-22 2008-02-12 Alantos Pharmaceuticals Holding Inc Inhibidores de la dipeptidil peptidasa-iv.
GB0514686D0 (en) * 2005-07-18 2005-08-24 Novartis Ag Organic compounds
CN1985878B (zh) * 2005-12-20 2011-06-22 广州王老吉药业股份有限公司 一种治疗消化性溃疡的药物组合物及其制备方法
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
JP5433579B2 (ja) * 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 1,3−二置換−4−フェニル−1h−ピリジン−2−オン
ATE516272T1 (de) 2007-09-14 2011-07-15 Ortho Mcneil Janssen Pharm 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
TWI475995B (zh) 2007-09-14 2015-03-11 Janssen Pharmaceuticals Inc 1’,3’-二取代-4-苯基-3,4,5,6-四氫-2h,1’h-〔1,4’〕聯吡啶基-2’-酮化物
AU2008323287B2 (en) * 2007-11-14 2011-07-14 Addex Pharma S.A. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
SG172382A1 (en) 2008-12-23 2011-07-28 Hoffmann La Roche Dihydropyridone ureas as p2x7 modulators
KR101370185B1 (ko) 2008-12-23 2014-03-05 에프. 호프만-라 로슈 아게 P2x7 조절제로서의 디히드로피리돈 아미드
US8153808B2 (en) 2008-12-23 2012-04-10 Roche Palo Alto Llc Dihydropyridone amides as P2X7 modulators
CA2745864A1 (en) 2008-12-23 2010-07-01 F.Hoffmann-La Roche Ag Dihydropyridone amides as p2x7 modulators
AU2009331667A1 (en) 2008-12-23 2010-07-01 F. Hoffmann-La Roche Ag Dihydropyridone amides as P2X7 modulators
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2012062751A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
EP3424535A1 (en) 2014-01-21 2019-01-09 Janssen Pharmaceutica NV Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3406329A1 (de) * 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
DK0955294T3 (da) * 1989-06-14 2004-02-02 Smithkline Beecham Corp Imidazolylalkensyre
CA2018443A1 (en) * 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids
JP2568315B2 (ja) * 1989-06-30 1997-01-08 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー 縮合環アリール置換イミダゾール
CA2027937A1 (en) * 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
US5399566A (en) * 1990-06-19 1995-03-21 Meiji Seika Kabushiki Kaisha Pyridine derivatives having angiotensin II antagonism

Also Published As

Publication number Publication date
CN1078468A (zh) 1993-11-17
CZ15793A3 (en) 1993-12-15
EP0557843A3 (en) 1993-12-01
IL104843A0 (en) 1993-06-10
HU9300545D0 (en) 1993-05-28
TW230206B (enExample) 1994-09-11
NZ245999A (en) 1995-10-26
AU3377093A (en) 1993-09-02
ZA931370B (en) 1993-03-23
HUT64057A (en) 1993-11-29
PL297870A1 (en) 1993-10-04
CA2090267A1 (en) 1993-08-28
AU653288B2 (en) 1994-09-22
MX9300766A (es) 1993-08-01
MY129973A (en) 2007-05-31
SK14593A3 (en) 1993-10-06
EP0557843A2 (de) 1993-09-01
JPH0641081A (ja) 1994-02-15
KR930017898A (ko) 1993-09-20
US5254543A (en) 1993-10-19

Similar Documents

Publication Publication Date Title
DE4206045A1 (de) Sulfonylbenzyl substituierte pyridone
EP0542059B1 (de) Substituierte Biphenylpyridone als Angiotensin II Antagonisten
EP0624583B1 (de) Substituierte Pyridylmethylpyridone als Angiotensin II Antagonisten
EP0611767B1 (de) Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate als Angiotensin II Antagonisten
EP0569795B1 (de) Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
DE4208051A1 (de) Substituierte phenylessigsaeureamide
EP0539713A1 (de) Substituierte Imidazolylpropensäurederivate als Angiotensin II Inhibitoren
EP0610698B1 (de) Substituierte Imidazo(4,5-b)pyridine und Benzimidazole als Angiotensin II Antagoniste
DE4132633A1 (de) Cyclisch substituierte imidazolyl-propensaeurederivate
DE4215588A1 (de) Biphenylmethyl-substituierte Pyridone
DE4208052A1 (de) Imidazolyl substituierte phenylessigsaeureamide
EP0610697B1 (de) Imidazolyl-substituierte Phenylessigsäureprolinamide
EP0617035B1 (de) Hetero-tricyclisch-substituierte Phenyl-cyclohexan-carbonsäurederivate
DE4301900A1 (de) 2-Oxochinolin-1-yl-methylphenylessigsäurederivate
EP0630896A1 (de) Substituierte Mono- und Bipyridylmethylderivate als Angiotensin II Antagonist
DE4212796A1 (de) Propenoyl-imidazolderivate
EP0622358A1 (de) Phenylglycinamide von 4-Imidazolylmethyl-Phenylessigsäuren und ihre Verwendung gegen Bluthochdruck und Atherosklerose
EP0581003B1 (de) Imidazolyl-substituierte Cyclohexanderivate
EP0623610A1 (de) Substituierte Pyridine und 2-Oxo-1,2-dihydropyridine als Angiotensin II Antagonisten
DE4206041A1 (de) Sulfonylbenzyl-substituierte imidazolylpropensaeurederivate
EP0623611A1 (de) Pyridinylmethyl-substituierte Pyridine und Pyridone als Angiotensin II Antagonisten
DE4206042A1 (de) Sulfonylbenzyl-substituierte imidazopyridine
DE4206043A1 (de) Sulfonylbenzyl-substituierte imidazole
DE4327256A1 (de) Sulfonylbenzyl-substituierte Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln
DE4210787A1 (de) Cycloalkyl- und Heterocyclyl substituierte Imidazolylpropensäurederivate

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee